Answers are grounded in this paper and cite their sources.
Case report reveals dupilumab's effectiveness treating bullous pemphigoid induced by nivolumab, highlighting its potential application.
Immune checkpoint inhibitors, a relatively new class of drugs, are used to treat a variety of malignancies. These drugs have a known association with cutaneous side effects, such as bullous pemphigoid. Bullous pemphigoid is a pruritic blistering disorder that is caused by autoantibodies forming against the basement membrane of the epidermis. New research has shown that interleukin-4, interleukin-13, and eosinophils play a significant role in the pathogenesis of bullous pemphigoid. Dupilumab, an IL4 alpha receptor antagonist has been shown to reduce IL4 and IL13 in atopic dermatitis. We present a case of nivolumab-induced bullous pemphigoid that was successfully treated with dupilumab.
No takes yet. Share an insight, caveat, or question.
Klepper et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: